Purpose of this Study
We are doing this study to see if an experimental drug called RMC-6236 (the study drug) is a safe and effective option for treating colorectal or pancreatic cancer when it is combined with different chemotherapy drugs.
Who Can Participate?
Eligibility
Adults ages 18+ who:
- Are diagnosed with metastatic or unresectable colorectal cancer; OR
- Are diagnosed with metastatic pancreatic cancer
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
If you choose to join this study, you will:
- Receive the study drug and chemotherapy with or without irinotecan, or with bevacizumab
- Have a tumor biopsy done, if necessary
- Have blood draws
- Have imaging scans (CT or MRI)
Locations
Duke University Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Study of RMC-6236 in Combination with 5-flourouracil-based Regimens in Patients with Unresectable or Metastatic Colorectal Cancer or Metastatic Pancreatic Ductal Adenocarcinoma– Subprotocol A
Principal Investigator
John
Strickler
Protocol Number
PRO00115657
NCT ID
NCT06445062
Phase
I/II
Enrollment Status
Open to Enrollment